share_log

Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target

Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target

尼德姆重申买入BioCryst Pharma,维持12美元的目标股价
Benzinga ·  01/08 05:52

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $12 price target.

尼德姆分析师塞尔吉·贝兰格重申BioCryst Pharma(纳斯达克股票代码:BCRX)的买入并维持12美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发